The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...